{"id":"W2522134251","doi":"10.1182/blood.v120.21.411.411","title":"Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Cytarabine; Oncology; Clinical endpoint; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001416679,0.001809121,0.002232283,0.0004415127,0.0004039139,0.001180399,0.00107387,0.001656494,0.004226447],"category_scores_gemma":[0.001182417,0.0009404634,0.001404471,0.0004575221,0.00149218,0.001081754,0.0004537991,0.004315499,0.001023398],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009380114,"about_ca_system_score_gemma":0.001835961,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008921509,"about_ca_topic_score_gemma":0.00213003,"domain_scores_codex":[0.9995091,0.0002623409,0.0000259414,0.00007746652,0.00003424595,0.00009095504],"domain_scores_gemma":[0.9989506,0.0002097872,0.0002102523,0.00008767363,0.00005058158,0.0004909757],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9033404,0.0490261,0.001412489,0.0003992027,0.0006949884,0.00009166526,0.0001457661,0.00112859,0.0204058,0.0001750446,0.00114723,0.02203256],"study_design_scores_gemma":[0.7099759,0.2846099,0.002000612,0.00001564696,0.0002875849,0.00006512587,0.00003458133,0.0004906868,0.001592077,0.0001586516,0.0007501263,0.00001907196],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.98992,0.001270195,0.0007727225,0.0004351466,0.0001426156,0.004864267,0.001112728,0.00009843373,0.001383864],"genre_scores_gemma":[0.9830658,0.001721484,0.002413186,0.001000712,0.0002396061,0.006335293,0.002003166,0.00004658488,0.0031741],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004226447,"threshold_uncertainty_score":0.01413888,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01594844810660552,"score_gpt":0.285311922298438,"score_spread":0.2693634741918325,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}